Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Two different enzyme preparations, agalsidase alfa (Replagal(TM), Shire) and beta (Fabrazyme(TM), Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized controlled open label trial. METHODOLOGY/PRINCIPAL FINDINGS: Thirty-four Fabry disease patients were treated with either agalsidase alfa or agalsidase beta at equal dose of 0.2 mg/kg biweekly. Primary endpoint was reduction in left ventricular mass after 12 and 24 months of treatment. Other endpoints included occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), glomerular filtration rate, pain, anti-agalsidase antibodies, and globotriaosylceramide levels in plasma and urine. After 12 and 24 months of treatment no reduction in left ventricular mass was seen, which was not different between the two treatment groups. Also, no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. Antibodies developed only in males (4/8 in the agalsidase alfa group and 6/8 in the agalsidase beta group). Treatment failure within 24 months of therapy was seen in 8/34 patients: 6 male patients (3 in each treatment group) and 2 female patients (both agalsidase alfa). The occurrence of treatment failures did not differ between the two treatment groups; chi(2) = 0.38 p = 0.54. CONCLUSION: Our study revealed no difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly. Treatment failure occurred frequently in both groups and seems related to age and severe pre-treatment disease. TRIAL REGISTRATION: International Standard Randomized Clinical Trial ISRCTN45178534 [http://www.controlled-trials.com/ISRCTN45178534].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Self-citationEnzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302 · cited 5×
“Both products have shown their effectiveness in reducing GL-3 in tissue biopsies [6,7], have favorable effect on renal function [8,9] and reduce cardiac mass in patients with cardiac hypertrophy [8,10].”
BackgroundMethodResultInfluentialEnzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053 · cited 1×
“Fabry disease is an X-linked lysosomal storage disorder caused by the deficiency of the lysosomal enzyme a-galactosidase A (aGal A, OMIM 301500)[1,2] resulting in lysosomal accumulation of globotriaosylceramide (GL-3) in endothelial cells and other cell types in the body.”
BackgroundEchocardiographic criteria for left ventricular hypertrophy: The Framingham heart study
Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel, W. B., & Castelli, W. P. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91133-7 · Cited by 799 · cited 1×
“Left ventricular hypertrophy was assessed by ultrasound (General Electric Vivid 7) as earlier described (LVmass >259 g in males and >166 g in females”
MethodMacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681 · cited 1×
“Recently it has become clear that female carriers can also exhibit complications, although the disease usually has a more attenuated course in these patients [5].”
Backgroundα-Galactosidase A deficiency. Fabry disease
Desnick, R. J. (2001) · Cited by 605
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
Cited by
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Zarate, Y. A., & Hopkin, R. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61589-5 · Cited by 795
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Aerts, J. M., Groener, J. E., Kuiper, S., Donker-Koopman, W. E., Strijland, A., Ottenhoff, R., van Roomen, C., Mirzaian, M., Wijburg, F. A., Linthorst, G. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712309105 · Cited by 731
Self-citation
Metadata
- Authors
- Vedder, A. C., Linthorst, G. E., Houge, G., Groener, J. E. M., Ormel, E. E., Bouma, B. J., Aerts, J. M. F. G., Hirth, A., & Hollak, C. E. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-07-11
- Volume
- 2
- Issue
- 7
- Pages
- e598
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2071598008
- Cited by
- 192
- References
- 31
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg. https://app.cochat.ai/papers/10.1371/journal.pone.0000598
- The paper
- Vedder, A. C., Linthorst, G. E., Houge, G., Groener, J. E. M., Ormel, E. E., Bouma, B. J., Aerts, J. M. F. G., Hirth, A., & Hollak, C. E. M. (2007). Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg. PLoS ONE. https://doi.org/10.1371/journal.pone.0000598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.